<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4">
    <dcterms:title><![CDATA[<p><strong>The Influence of Cardiovascular Physiology on Dose/Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Relationships</strong></p>]]></dcterms:title>
    <dcterms:subject><![CDATA[FARMACOCIN&Eacute;TICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2006]]></dcterms:subject>
    <dcterms:subject><![CDATA[CARDIOLOGIA]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Inter- and intraindividual variability in the relationship between dose and clinical &ndash; or pharmacodynamic &ndash; response of a drug can be analysed in two steps: firstly, by considering the plasma pharmacokinetic response to a given dose and, secondly, by the connection between both pharmacokinetic and pharmacodynamic responses. As the cardiovascular system is the means of transport of endogenous and exogenous substances, blood flow fraction destined to each organ determines the relative mass of solute in plasma, which is constantly in contact with the tissue. Hence, not only the rate but also the extent of drug transfer would be increased when tissues are irrigated by a higher fraction of cardiac output. Aging and circadian rhythms present similar cardiac output distribution patterns when moving from young to aged adult and from nocturnal to diurnal hours. These two changes lead to an increased blood flow delivery to the extra-splanchnic-renal region in the elderly and in the morning, but with a decreased cardiac output in aged individuals and an increased one during the day. This scenario allows us to forecast substance concentrations outside the blood vessels, which are responsible for the extent of drug elimination and the intensity]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=caabbc98478c9c9fb71e4b0eb4e4ccd5"><strong>Fagiolino, Pietro</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Eiraldi, Rosa</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>V&aacute;zquez, Marta</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Clinical Pharmacokinetics. v.45, n&ordm; 5, 2006. -- p. 433-448.]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer]]></dcterms:publisher>
    <dcterms:date><![CDATA[2006]]></dcterms:date>
    <dcterms:rights><![CDATA[<em><strong>Informaci&oacute;n sobre Derechos de Autor</strong></em><br />(Por favor lea este aviso antes de abrir los documentos u objetos)<br /><em><strong>La legislaci&oacute;n uruguaya</strong></em>&nbsp;protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)<br /><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.2165/00003088-200645050-00001]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/53">
    <dcterms:title><![CDATA[<strong>Cloning and Functional Studies of a Splice Variant of CYP26B1 Expressed in Vascular Cells</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ACIDO TRANS-RETINOICO]]></dcterms:subject>
    <dcterms:subject><![CDATA[CLONACION MOLECULAR]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2012]]></dcterms:subject>
    <dcterms:subject><![CDATA[CELULAS VASCULARES]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<p>Background: All-trans retinoic acid (atRA) plays an essential role in the regulation of gene expression, cell growth and differentiation and is also important for normal cardiovascular development but may in turn be involved in cardiovascular diseases, i.e. atherosclerosis and restenosis. The cellular atRA levels are under strict control involving several cytochromes P450 isoforms (CYPs). CYP26 may be the most important regulator of atRA catabolism in vascular cells. The present study describes the molecular cloning, characterization and function of atRA-induced expression of a spliced variant of the CYP26B1 gene.<br />Methodology/Principal Findings: The coding region of the spliced CYP26B1 lacking exon 2 was amplified from cDNA synthesized from atRA-treated human aortic smooth muscle cells and sequenced. Both the spliced variant and full length CYP26B1 was found to be expressed in cultured human endothelial and smooth muscle cells, and in normal and atherosclerotic vessel. atRA induced both variants of CYP26B1 in cultured vascular cells. Furthermore, the levels of spliced mRNA transcript were 4.5 times higher in the atherosclerotic lesion compared to normal arteries and the expression in the lesions was increased 20-fold upon atRA treatment. The spliced CYP26B1 still has the capability to degrade atRA, but at an initial rate one-third that of the corresponding full length enzyme. Transfection of COS-1 and THP-1 cells with the CYP26B1 spliced variant indicated either an increase or a decrease in the catabolism of atRA, probably depending on the expression<br />of other atRA catabolizing enzymes in the cells.<br />Conclusions/Significance: Vascular cells express the spliced variant of CYP26B1 lacking exon 2 and it is also increased in atherosclerotic lesions. The spliced variant displays a slower and reduced degradation of atRA as compared to the fulllength enzyme. Further studies are needed, however, to clarify the substrate specificity and role of the CYP26B1 splice variant in health and disease.</p>
<p style="margin-bottom: 0cm;">&nbsp;</p>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Elmabsout, A. A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Kumawat, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=f4e5f5966e2f949cc6ad308da8978be6" target="_blank"><strong>Saenz-M&eacute;ndez, Patricia</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Krivospitskaya, O</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Savenstrand, H</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Olofsson, P. S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Eriksson, L. A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Strid, A</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Valen, G.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Torma,&nbsp; H.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sirsjo, A</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[PloS One v. 7, no. 5, 2012. -- e36839]]></dcterms:source>
    <dcterms:publisher><![CDATA[de Windt, Leon J.]]></dcterms:publisher>
    <dcterms:date><![CDATA[2012]]></dcterms:date>
    <dcterms:rights><![CDATA[<p align="LEFT"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p style="margin-bottom: 0cm;"><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<p><br /><br /></p>
<p style="margin-bottom: 0cm;">&nbsp;</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.1371/journal.pone.0036839]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/2436">
    <dcterms:title><![CDATA[<strong>In vitro approach to study the influence of the cardiac output distribution on drug concentration</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[CARDIOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[SANGRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[SISTEMA CARDIOVASCULAR]]></dcterms:subject>
    <dcterms:subject><![CDATA[PRODUCTOS FARMACEUTICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Blood flow is not constant during the day, not only due to cardiac output variation but to the variable blood flow fraction supplied to the organs. To what extent these variations could affect the relative drug concentration between two different tissues, is the purpose of this work. In order to study that, a device was designed which took into account different fluid flows towards two flasks. Connections between flasks and pump are shown in text (figure 1). At the bottom of each flask a non-miscible liquid (dichloromethane: CH2Cl2, 100 mL, places 2 and 3) with the circulating fluid (water, 1350 mL, places 1, A, B) was placed. Malachite Green (MG) was introduced as solute into the system (place 1,5 mL, 700 mg/L aqueous solution). The pump output was set at 1080 mL/min, serving more fluid (five times) to flask A than to flask B. Samples were drawn from compartments 1, A and B, and from organic compartments, during experiences taking several hours. MG concentrations were colorimetrically measured at 619 nm. Room temperature was between 15&ndash;25 &deg;C. CH2Cl2 MG concentration ratio ([2]/[3]) was similar to fluid flow ratio (&sigma;/(1-&sigma;)) all over the experience time. Other experiences changing the stop time, room temperature, CH2Cl2 volumes and places, pump output distribution, led us to different evidences that supported a theoretical model. As a conclusion, the most important feature was that whereas MG concentrations in water (1, A, B) were close, in CH2Cl2 these were very different. So, is drug effect prediction reliable by monitoring free drug concentrations in blood? European Journal of Drug Metabolism and Pharmacokinetics European Journal of Drug Metabolism and Pharmacokinetics Look Inside Article Metrics 3 Citations Co-published with Adis Adis Other actions Export citation Register for Journal Updates About This Journal Reprints and Permissions Add to Papers Share Share this content on Facebook Share this content on Twitter Share this content on LinkedIn]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Fagiolino, Pietro</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wilson, F.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Samaniego, E.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Vazquez, M.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[European Journal of Drug Metabolism and Pharmacokinetics v. 28, no. 2, 2003. -- p. 147-153]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer]]></dcterms:publisher>
    <dcterms:date><![CDATA[2003]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1007/BF03190504]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5216">
    <dcterms:title><![CDATA[<strong>Farmacodinamica de los analg&eacute;sicos menores : acci&oacute;n sobre los distintos aparatos y sistemas (sistema nervioso, card&iacute;aco y circulatorio, h&iacute;gado y su excreci&oacute;n)</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[<strong>ANALGESICOS Y ANTIPIRETICOS</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>FARMACOLOGIA</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>SISTEMA NERVIOSO</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>SISTEMA CARDIOVASCULAR</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>HIGADO</strong>]]></dcterms:subject>
    <dcterms:publisher><![CDATA[Biblioteca-FQ]]></dcterms:publisher>
    <dcterms:date><![CDATA[1985]]></dcterms:date>
    <dcterms:format><![CDATA[Papel]]></dcterms:format>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Bibliograf&iacute;a]]></dcterms:type>
    <dcterms:temporal><![CDATA[1970-1984]]></dcterms:temporal>
</rdf:Description></rdf:RDF>
